Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation

Transplantation

Volumn 75, Issue 12, 2003, Pages 2064-2068

  Westall, Glen P ^a   Michaelides, Alexandra ^a   Williams, Trevor J ^a   Snell, Greg I ^a   Kotsimbos, Thomas C ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS DNA; GANCICLOVIR; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; ARTICLE; BRONCHIOLITIS; CLINICAL ARTICLE; COHORT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; FEMALE; FORCED EXPIRATORY VOLUME; GRAFT REJECTION; HUMAN; HUMAN CYTOMEGALOVIRUS DNAAEMIA; LUNG TRANSPLANTATION; MALE; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; QUANTITATIVE GENETICS; RISK FACTOR; SERODIAGNOSIS; VIRUS DETECTION; VIRUS DIAGNOSIS; VIRUS LOAD; VIRUS PNEUMONIA; VIRUS REACTIVATION;

EID: 0038789133     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000069234.04901.A3     Document Type: Article

References (30)

1. Levine SM, Byran CL. Bronchiolitis obliterans in lung transplant recipients. The "thorn in the side" of lung transplantation. Chest 1995; 107: 894.
2. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297.
3. Keenan RJ, Lega ME, Dummer JS, et al. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation 1991; 51: 433.
4. Gutierrez CA, Chaparro C, Krajden M, et al. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. Chest 1998; 113: 924.
5. Griffiths PD, Cope AV, Hassan-Walker AF, et al. Diagnostic approaches to cytomegalovirus infection in bone marrow and organ transplantation. Transpl Infect Dis 1999; 1: 179.
6. Michaelides A, Liolios L, Glare EM, et al. Increased human cytomegalovirus (HCMV) DNA load in peripheral blood leukocytes after lung transplantation correlates with HCMV pneumonitis. Transplantation 2001; 72: 141.
7. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094.
8. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation of the classification of pulmonary allograft rejection. Lung Rejection Study Group. J Heart Lung Transplant 1996; 15: 1.
9. Kotsimbos AT, Sinickas V, Glare EM, et al. Quantitative detection of human cytomegalovirus DNA in lung transplant recipients. Am J Respir Crit Care Med 1997; 156: 1241.
10. Smith MA, Sundaresan S, Mohanakumar T, et al. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thoracic Cardiovasc Surg 1998; 116: 812.
11. Heng D, Sharples LD, McNeil K, et al. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 1998; 17: 1255.
12. Kroshus TJ, Kshettey VR, Savik K, et al. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997; 114: 195.
13. Girgis RE, Tu I, Berry GJ, et al. Risk factors for the development of bronchiolitis obliterans after lung transplantation. J Heart Lung Transplant 1996; 15: 1200.
14. Husain AN, Siddiqui MT, Holmes EW, et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 1999; 159: 829.
15. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462.
16. Egan JJ, Caroll KB, Yonan N, et al. Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomised trial. J Heart Lung Transplant 2002; 21: 460.
17. Duncan SR, Paradis IL, Yousem SA, et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 1992; 146: 1419.
18. Soghikian MV, Valentine VG, Berry GJ, et al. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant 1996; 15: 881.
19. Speich R, Thurnheer R, Gaspert A, et al. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Transplantation 1999; 67: 315.
20. Riise GC, Andersson R, Bergstrom T, et al. Quantification of cytomegalovirus DNA in BAL fluid. A longitudinal study in lung transplant recipients. Chest 2000; 118: 1653.
21. Higenbottam T, Stewart S, Penketh A, et al. The diagnosis of lung rejection and opportunistic infection by transbronchial lung biopsy. Transplant Proc 1987; 19: 3777.
22. Burke CM, Glanville AR, Theodore J, et al. Lung immunogenicity, rejection and obliterative bronchiolitis. Chest 1987; 92: 547.
23. Borysiewicz LK, Graham S, Hickling JK, et al. Human cytomegalovirus-specific cytotoxic T cells: their precursor frequency and stage specificity. Eur J Immunol 1988; 18: 269.
24. Chang SC, Hsu HK, Perng RP, et al. Increased expression of MHC class II antigens in rejecting canine lung allografts. Transplantation 1990; 49: 1158.
25. Smyth RL, Scott JP, Borysiewicz LK, et al. Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment. J Infect Dis 1991; 164: 1045.
26. You XM, Steinmuller C, Wagner TO, et al. Enhancement of cytomegalovirus infection and acute rejection after allogenic lung transplantation in the rat: virus-induced expression ofmajor histocompatibility complex class II antigens. J Heart Lung Transplant 1996; 15: 1108.
27. Geist LJ, Dai LY. Cytomegalovirus modulates interleukin-6 gene expression. Transplantation 1996; 62: 653.
28. Burns LJ, Pooley JC, Walsh DJ, et al. Intercellular adhesion molecule-1 expression in endothelial cells is activated by cytomegalovirus immediate early proteins. Transplantation 1999; 67: 137.
29. Burrows SR, Khanna R, Silins SL, et al. The influence of antiviral T-cell responses on the alloreactive repertoire. Immunol Today 1999; 20: 203.
30. Carney WP, Rubin RH, Hoffman RA, et al. Analysis of T lymphocyte subsets in cytomegalovirus mononucleosis. J Immunol 1981; 126: 2114.